Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SLC10A1 | Q14973 | 6/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28497756 | 1.00 | KMT2A (0.42) | KMT2AUSP2THRBSLC10A1HPGD | |
| SCHEMBL22906168 | 1.00 | KMT2A (0.42) | KMT2AUSP2THRBSLC10A1HPGD | |
| SCHEMBL25645222 | 0.87 | KMT2A (0.47) | KMT2AUSP2THRBHPGDALDH1A1 | |
| SCHEMBL22973695 | 0.84 | SLC10A1 (0.40) | SLC10A1 | |
| SCHEMBL21427855 | 0.84 | SLC10A1 (0.40) | SLC10A1 | |
| SCHEMBL22973694 | 0.84 | SLC10A1 (0.40) | SLC10A1 | |
| SCHEMBL28898144 | 0.81 | KMT2A (0.41) | KMT2AUSP2THRBHPGDALDH1A1 | |
| SCHEMBL21428269 | 0.79 | KMT2A (0.49) | KMT2AUSP2THRBHPGDALDH1A1 | |
| SCHEMBL22906154 | 0.76 | KMT2A (0.51) | KMT2AUSP2THRBHPGDALDH1A1 | |
| SCHEMBL22307951 | 0.76 | SLC10A1 (0.53) | SLC10A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116356-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-10-15 | — | — | US | disclosed |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| CN-115974753-A | N-containing heterocyclic five-membered ring compound and application | 正大天晴药业集团股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115974754-A | N-containing heterocyclic five-membered ring compound and application | 正大天晴药业集团股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-11597716-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-03-07 | — | — | US | disclosed |
| EP-3778569-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017154-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| CN-111868026-A | Capsid protein assembly inhibitor containing N-heterocyclic five-membered ring, pharmaceutical composition and application thereof | 正大天晴药业集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597716-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | COG5, HAVCR2, ZC3HAV1 | KMT2A 4197/4885USP2 1858/4885THRB 2557/4885 |
| US-12116356-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | COG5, HAVCR2, ZC3HAV1 | KMT2A 4197/4885USP2 1858/4885THRB 2557/4885 |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | COG5, HAVCR2, ZC3HAV1 | KMT2A 4197/4885USP2 1858/4885THRB 2557/4885 |
| US-20210017154-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | COG5, HAVCR2, ZC3HAV1 | KMT2A 4197/4885USP2 1858/4885THRB 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.